Proud D, Naclerio R M, Togias A G, Kagey-Sobotka A, Adkinson N F, Norman P A, Lichtenstein L M
Adv Exp Med Biol. 1986;198 Pt B:181-7. doi: 10.1007/978-1-4757-0154-8_22.
We have demonstrated that kinins are generated following nasal challenge with allergen of allergic (5.6 +/- 0.17 ng/m-), but not nonallergic (0.04 +/- .02 ng/ml), individuals (n = 8 in each case). The presence of kinin was highly correlated with that of histamine and TAME-esterase activity and with clinical symptoms (p less than 0.001). In a double blind, placebo-controlled study, topical administration of the drug Azatadine, which inhibits mast cell mediator release in vitro, reduced the clinical response to allergen challenge and reduced the concentrations of kinins, histamine, and TAME-esterase activity observed following allergen challenge. In addition to the immediate response to allergen, some individuals experience a recurrence of symptoms some 3-12 hours after challenge; in seven such individuals (13.5 +/- 3.2 ng kinin/ml in the immediate reaction), there was a second increase in nasal kinins (2.95 +/- 1.4 ng/ml) during this late reaction, again correlating with increases in histamine and TAME-esterase activity. HPLC analysis revealed that a mixture of bradykinin and lysylbradykinin is produced during both responses. Finally, 12 subjects with a history of nasal symptoms upon exposure to cold, dry air (CDA) were compared to five asymptomatic individuals in a nasal challenge system involving nasal breathing of CDA and warm, moist air (WMA). For the symptomatic group the levels of kinin in nasal lavages were significantly increased after CDA (2.9 +/- 0.8 ng/ml) compared to baseline (0.06 +/- 0.01 ng/ml) or WMA (0.3 +/- 0.07 ng/ml). Kinin generation again correlated with increases in histamine, PGD2 and TAME-esterase activity and with onset of symptoms.(ABSTRACT TRUNCATED AT 250 WORDS)
我们已经证明,过敏性个体(5.6±0.17纳克/毫升)在鼻腔接触过敏原后会产生激肽,而非过敏性个体(0.04±0.02纳克/毫升)则不会产生(每组n = 8)。激肽的存在与组胺、TAME酯酶活性以及临床症状高度相关(p<0.001)。在一项双盲、安慰剂对照研究中,局部应用药物阿扎他定(该药物在体外可抑制肥大细胞介质释放)可降低对过敏原激发的临床反应,并降低过敏原激发后观察到的激肽、组胺浓度以及TAME酯酶活性。除了对过敏原的即时反应外,一些个体在激发后约3 - 12小时会出现症状复发;在7名此类个体中(即时反应中激肽为13.5±3.2纳克/毫升),在这种迟发反应期间鼻腔激肽再次升高(2.95±1.4纳克/毫升),同样与组胺和TAME酯酶活性增加相关。高效液相色谱分析显示,在两种反应过程中均产生了缓激肽和赖氨酰缓激肽的混合物。最后,在一个涉及鼻腔呼吸冷空气、干燥空气(CDA)和温暖、潮湿空气(WMA)的鼻腔激发系统中,将12名有接触冷、干空气(CDA)后出现鼻部症状病史的受试者与5名无症状个体进行了比较。对于有症状组,与基线(0.06±0.01纳克/毫升)或WMA(0.3±0.07纳克/毫升)相比,CDA后鼻腔灌洗中的激肽水平显著升高(2.9±0.8纳克/毫升)。激肽生成再次与组胺、前列腺素D2和TAME酯酶活性增加以及症状发作相关。(摘要截选至250字)